Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Study of Cetuximab Plus Irinotecan in Patients With EGFR-detectable Metastatic Colorectal Carcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* The subject must have surgically unresectable metastatic colorectal carcinoma.~* The subjects who have received and failed Ilinotecan, oxaliplatin and fluoropyrimidine-based chemotherapy~* ECOG PS 0-2~Exclusion Criteria:~* Subjects with symptomatic cerebral metastasis

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).